by Portfolio Grader | December 6, 2013 9:15 am
For the current week, the overall ratings of three pharmaceutical stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, VIVUS, Inc. (VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. In Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. As of Dec. 6, 2013, 30.9% of outstanding VIVUS, Inc. shares were held short. To get an in-depth look at VVUS, get Portfolio Grader’s complete analysis of VVUS stock.
This week, Cempra, Inc.’s (CEMP) rating worsens to a D from the company’s C rating a week ago. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics Incorporated. (CORT) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For a full analysis of CORT stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/12/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort-33/
Short URL: http://invstplc.com/1fuoBoa
Copyright ©2016 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.